AI assistant
Sending…
Moberg Pharma — Major Shareholding Notification 2019
Sep 13, 2019
3174_iss_2019-09-13_f2bc9452-d18c-42c9-84be-798316bf4206.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer

Issuer Moberg Pharma AB (publ)
Holder
Armistice Capital LLC (Delaware US LLC)
Instrument
| Instrument | Shares | |
|---|---|---|
| Before the transaction | ||
| Shares | Data not given* | |
| Voting rights | Data not given* | |
| Transaction | ||
| Reason for major shareholding notification Sell | ||
| Date | 01/04/2019 | |
| Limit for number of shares | 5 % | |
| Limit for number of votes | 5 % | |
| After the transaction | ||
| Quantity | ||
| Shares | 853,458 | |
| Directly held voting rights | 0 | |
| Indirectly held voting rights | 853,458 | |
| Percentage | ||
| Directly held shares | 4.98989 % | |
| Directly held voting rights | 0 % | |
| Indirectly held voting rights | 4.98989 % |
Resulting distribution of total holdings
| Percentage of voting rights: |
Number of underlying shares: |
|
|---|---|---|
| Shares | 4.98989 % | 853,458 |
| Instruments - FITA Ch. 4, section 2, first paragraph, line 2 Instruments - FITA Ch. 4, section 2, first paragraph, line 3 |
||
| - Physically settled - Cash settled |
||
| Total | 4.98989 % | 853,458 |
| Chain of controlling companies Voting rights % Voting rights Company |
||
| 853,458 4.98989 |
Armistice Capital Master Fund Ltd | |
| Group total holdings |
||
| Voting rights 853,458 |
||
| Percentage of voting rights 4.98989 | ||
| Published | ||
| 13/09/2019 14:01 | ||
| Contact | ||
| Name Daniel Radden Phone 212 231-4937 Email [email protected] |
*Source of information has chosen not to submit the data
CLOSE PRINT
[email protected] Tfn 08-408 980 37 Fax 08-24 39 25
More from Moberg Pharma
Declaration of Voting Results & Voting Rights Announcements
2026
May 21
Declaration of Voting Results & Voting Rights Announcements
2026
May 21
Interim / Quarterly Report
2026
May 12
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
Apr 24
Regulatory Filings
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 17
AGM Information
2026
Apr 17
Annual Report
2026
Apr 17
Regulatory Filings
2026
Mar 13